ID   AKT2_HUMAN              Reviewed;         481 AA.
AC   P31751; B2RBD8; Q0VAN1; Q68GC0;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 2.
DT   02-NOV-2010, entry version 118.
DE   RecName: Full=RAC-beta serine/threonine-protein kinase;
DE            EC=2.7.11.1;
DE   AltName: Full=Protein kinase Akt-2;
DE   AltName: Full=Protein kinase B beta;
DE            Short=PKB beta;
DE   AltName: Full=RAC-PK-beta;
GN   Name=AKT2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Epithelium;
RX   MEDLINE=92198987; PubMed=1801921;
RA   Jones P.F., Jakubowicz T., Hemmings B.A.;
RT   "Molecular cloning of a second form of rac protein kinase.";
RL   Cell Regul. 2:1001-1009(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=93028445; PubMed=1409633; DOI=10.1073/pnas.89.19.9267;
RA   Cheng J.Q., Godwin A.K., Bellacosa A., Taguchi T., Franke T.F.,
RA   Hamilton T.C., Tsichlis P.N., Testa J.R.;
RT   "AKT2, a putative oncogene encoding a member of a subfamily of
RT   protein-serine/threonine kinases, is amplified in human ovarian
RT   carcinomas.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:9267-9271(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 237-277.
RG   NIEHS SNPs program;
RL   Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   CHARACTERIZATION, AND PHOSPHORYLATION AT THR-309 BY PDPK1.
RX   PubMed=9512493;
RA   Walker K.S., Deak M., Paterson A., Hudson K., Cohen P., Alessi D.R.;
RT   "Activation of protein kinase B beta and gamma isoforms by insulin in
RT   vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro:
RT   comparison with protein kinase B alpha.";
RL   Biochem. J. 331:299-308(1998).
RN   [7]
RP   INTERACTION WITH MTCP1; TCL1A AND TCL1B.
RX   PubMed=10983986; DOI=10.1016/S1097-2765(00)00039-3;
RA   Laine J., Kuenstle G., Obata T., Sha M., Noguchi M.;
RT   "The protooncogene TCL1 is an Akt kinase coactivator.";
RL   Mol. Cell 6:395-407(2000).
RN   [8]
RP   MUTAGENESIS OF THR-309 AND SER-474, AND PHOSPHORYLATION AT THR-309 AND
RP   SER-474.
RX   PubMed=15890450; DOI=10.1016/j.bbagen.2005.04.002;
RA   Baer K., Lisinski I., Gompert M., Stuhlmann D., Schmolz K.,
RA   Klein H.W., Al-Hasani H.;
RT   "Activation of a GST-tagged AKT2/PKBbeta.";
RL   Biochim. Biophys. Acta 1725:340-347(2005).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-126, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [11]
RP   UBIQUITINATION BY TTC3, PHOSPHORYLATION AT THR-309 AND SER-474, AND
RP   MUTAGENESIS OF THR-309 AND SER-474.
RX   PubMed=20059950; DOI=10.1016/j.devcel.2009.09.007;
RA   Suizu F., Hiramuki Y., Okumura F., Matsuda M., Okumura A.J.,
RA   Hirata N., Narita M., Kohno T., Yokota J., Bohgaki M., Obuse C.,
RA   Hatakeyama S., Obata T., Noguchi M.;
RT   "The E3 ligase TTC3 facilitates ubiquitination and degradation of
RT   phosphorylated Akt.";
RL   Dev. Cell 17:800-810(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-447; THR-451; SER-474
RP   AND SER-478, AND MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   UBIQUITINATION, AND INTERACTION WITH TRAF6.
RX   PubMed=19713527; DOI=10.1126/science.1175065;
RA   Yang W.-L., Wang J., Chan C.-H., Lee S.-W., Campos A.D., Lamothe B.,
RA   Hur L., Grabiner B.C., Lin X., Darnay B.G., Lin H.-K.;
RT   "The E3 ligase TRAF6 regulates Akt ubiquitination and activation.";
RL   Science 325:1134-1138(2009).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-188 AND LYS-208.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: General protein kinase capable of phosphorylating
CC       several known proteins.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Two specific sites, one in the kinase domain
CC       (Thr-309) and the other in the C-terminal regulatory region (Ser-
CC       474), need to be phosphorylated for its full activation.
CC   -!- SUBUNIT: Interacts (via PH domain) with MTCP1, TCL1A AND TCL1B.
CC       Interacts with TRAF6.
CC   -!- INTERACTION:
CC       Q16543:CDC37; NbExp=1; IntAct=EBI-296058, EBI-295634;
CC       P49841:GSK3B; NbExp=1; IntAct=EBI-296058, EBI-373586;
CC       Q15047:SETDB1; NbExp=1; IntAct=EBI-296058, EBI-79691;
CC       Q7Z6J0:SH3RF1; NbExp=1; IntAct=EBI-296058, EBI-311339;
CC   -!- TISSUE SPECIFICITY: Expressed in all human cell types so far
CC       analyzed.
CC   -!- PTM: Phosphorylation on Thr-309 and Ser-474 is required for full
CC       activity.
CC   -!- PTM: Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked
CC       polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT2
CC       ubiquitination. When fully phosphorylated and translocated into
CC       the nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed by
CC       TTC3, leading to its degradation by the proteasome.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. RAC subfamily.
CC   -!- SIMILARITY: Contains 1 AGC-kinase C-terminal domain.
CC   -!- SIMILARITY: Contains 1 PH domain.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/AKT2ID517ch19q13.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/akt2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M77198; AAA36585.1; -; mRNA.
DR   EMBL; M95936; AAA58364.1; -; mRNA.
DR   EMBL; AK314619; BAG37185.1; -; mRNA.
DR   EMBL; BC120994; AAI20995.1; -; mRNA.
DR   EMBL; AY708392; AAT97984.1; -; Genomic_DNA.
DR   IPI; IPI00012870; -.
DR   PIR; A46288; A46288.
DR   RefSeq; NP_001617.1; -.
DR   UniGene; Hs.631535; -.
DR   PDB; 1GZK; X-ray; 2.30 A; A=146-460.
DR   PDB; 1GZN; X-ray; 2.50 A; A=146-480.
DR   PDB; 1GZO; X-ray; 2.75 A; A=146-460.
DR   PDB; 1MRV; X-ray; 2.80 A; A=143-481.
DR   PDB; 1MRY; X-ray; 2.80 A; A=143-481.
DR   PDB; 1O6K; X-ray; 1.70 A; A=146-481.
DR   PDB; 1O6L; X-ray; 1.60 A; A=146-467.
DR   PDB; 1P6S; NMR; -; A=1-111.
DR   PDB; 2JDO; X-ray; 1.80 A; A=146-467.
DR   PDB; 2JDR; X-ray; 2.30 A; A=146-467.
DR   PDB; 2UW9; X-ray; 2.10 A; A=146-467.
DR   PDB; 2X39; X-ray; 1.93 A; A=146-467.
DR   PDB; 2XH5; X-ray; 2.72 A; A=146-467.
DR   PDB; 3D0E; X-ray; 2.00 A; A/B=146-480.
DR   PDB; 3E87; X-ray; 2.30 A; A/B=146-480.
DR   PDB; 3E88; X-ray; 2.50 A; A/B=146-480.
DR   PDB; 3E8D; X-ray; 2.70 A; A/B=146-480.
DR   PDBsum; 1GZK; -.
DR   PDBsum; 1GZN; -.
DR   PDBsum; 1GZO; -.
DR   PDBsum; 1MRV; -.
DR   PDBsum; 1MRY; -.
DR   PDBsum; 1O6K; -.
DR   PDBsum; 1O6L; -.
DR   PDBsum; 1P6S; -.
DR   PDBsum; 2JDO; -.
DR   PDBsum; 2JDR; -.
DR   PDBsum; 2UW9; -.
DR   PDBsum; 2X39; -.
DR   PDBsum; 2XH5; -.
DR   PDBsum; 3D0E; -.
DR   PDBsum; 3E87; -.
DR   PDBsum; 3E88; -.
DR   PDBsum; 3E8D; -.
DR   ProteinModelPortal; P31751; -.
DR   DisProt; DP00304; -.
DR   IntAct; P31751; 5.
DR   MINT; MINT-87790; -.
DR   STRING; P31751; -.
DR   PhosphoSite; P31751; -.
DR   PRIDE; P31751; -.
DR   Ensembl; ENST00000392038; ENSP00000375892; ENSG00000105221.
DR   Ensembl; ENST00000424901; ENSP00000399532; ENSG00000105221.
DR   GeneID; 208; -.
DR   KEGG; hsa:208; -.
DR   UCSC; uc002onf.1; human.
DR   CTD; 208; -.
DR   GeneCards; GC19M040736; -.
DR   H-InvDB; HIX0015131; -.
DR   HGNC; HGNC:392; AKT2.
DR   HPA; CAB004204; -.
DR   MIM; 164731; gene.
DR   Orphanet; 79085; Familial partial lipodystrophy due to AKT2 mutations.
DR   PharmGKB; PA24685; -.
DR   eggNOG; prNOG16694; -.
DR   HOGENOM; HBG755340; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; P31751; -.
DR   OMA; EEIRFPK; -.
DR   OrthoDB; EOG97H886; -.
DR   PhylomeDB; P31751; -.
DR   BRENDA; 2.7.11.1; 247.
DR   Pathway_Interaction_DB; pi3kciaktpathway; Class I PI3K signaling events mediated by Akt.
DR   Pathway_Interaction_DB; insulin_pathway; Insulin Pathway.
DR   Pathway_Interaction_DB; insulin_glucose_pathway; Insulin-mediated glucose transport.
DR   Reactome; REACT_11061; Signalling by NGF.
DR   Reactome; REACT_1123; Inhibition of HSL.
DR   Reactome; REACT_13698; Regulation of beta-cell development.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   Reactome; REACT_498; Signaling by Insulin receptor.
DR   Reactome; REACT_604; Hemostasis.
DR   Reactome; REACT_6900; Signaling in Immune system.
DR   BindingDB; P31751; -.
DR   NextBio; 836; -.
DR   ArrayExpress; P31751; -.
DR   Bgee; P31751; -.
DR   CleanEx; HS_AKT2; -.
DR   Genevestigator; P31751; -.
DR   GermOnline; ENSG00000105221; Homo sapiens.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:ProtInc.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0010748; P:negative regulation of plasma membrane long...; IMP:BHF-UCL.
DR   GO; GO:0032000; P:positive regulation of fatty acid beta-oxid...; IMP:BHF-UCL.
DR   GO; GO:0046326; P:positive regulation of glucose import; IMP:BHF-UCL.
DR   GO; GO:0045725; P:positive regulation of glycogen biosyntheti...; IMP:BHF-UCL.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR011993; PH_type.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR001849; Pleckstrin_homology.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   InterPro; IPR015744; Serine/threonine_Kinase_Rac.
DR   Gene3D; G3DSA:2.30.29.30; PH_type; 1.
DR   PANTHER; PTHR22985:SF69; Akt; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Complete proteome; Kinase;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN         1    481       RAC-beta serine/threonine-protein kinase.
FT                                /FTId=PRO_0000085608.
FT   DOMAIN        5    108       PH.
FT   DOMAIN      152    409       Protein kinase.
FT   DOMAIN      410    481       AGC-kinase C-terminal.
FT   NP_BIND     158    166       ATP (By similarity).
FT   ACT_SITE    275    275       Proton acceptor (By similarity).
FT   BINDING     181    181       ATP (By similarity).
FT   MOD_RES     126    126       Phosphoserine.
FT   MOD_RES     309    309       Phosphothreonine; by PDPK1.
FT   MOD_RES     447    447       Phosphoserine.
FT   MOD_RES     451    451       Phosphothreonine.
FT   MOD_RES     474    474       Phosphoserine.
FT   MOD_RES     478    478       Phosphoserine.
FT   VARIANT     188    188       I -> V (in dbSNP:rs55859611).
FT                                /FTId=VAR_040356.
FT   VARIANT     208    208       R -> K (in dbSNP:rs35817154).
FT                                /FTId=VAR_040357.
FT   MUTAGEN     309    309       T->A: Impairs interaction with TTC3; when
FT                                associated with A-474.
FT   MUTAGEN     309    309       T->E: Constitutively active; when
FT                                associated with D-474.
FT   MUTAGEN     474    474       S->A: Impairs interaction with TTC3; when
FT                                associated with A-309.
FT   MUTAGEN     474    474       S->D: Constitutively active; when
FT                                associated with E-309.
FT   CONFLICT    478    481       SIRE -> FREEKDLLMSLFVSLILFSDFSSLKSHSFSSNF
FT                                ILLSFSSLKK (in Ref. 1; AAA36585).
FT   STRAND        6     15
FT   STRAND       17     20
FT   STRAND       22     30
FT   TURN         31     33
FT   STRAND       34     40
FT   STRAND       45     47
FT   STRAND       52     56
FT   STRAND       58     60
FT   STRAND       62     65
FT   STRAND       67     75
FT   STRAND       86     92
FT   HELIX        93    110
FT   HELIX       149    151
FT   STRAND      152    160
FT   STRAND      162    171
FT   TURN        172    174
FT   STRAND      177    184
FT   TURN        185    187
FT   TURN        199    202
FT   HELIX       203    206
FT   STRAND      215    220
FT   STRAND      222    230
FT   HELIX       237    242
FT   HELIX       249    268
FT   HELIX       278    280
FT   STRAND      281    283
FT   STRAND      289    291
FT   HELIX       319    324
FT   HELIX       330    345
FT   STRAND      351    353
FT   HELIX       358    364
FT   HELIX       375    384
FT   HELIX       389    391
FT   TURN        397    399
FT   HELIX       400    404
FT   HELIX       414    418
SQ   SEQUENCE   481 AA;  55769 MW;  B18C87A7246BFB24 CRC64;
     MNEVSVIKEG WLHKRGEYIK TWRPRYFLLK SDGSFIGYKE RPEAPDQTLP PLNNFSVAEC
     QLMKTERPRP NTFVIRCLQW TTVIERTFHV DSPDEREEWM RAIQMVANSL KQRAPGEDPM
     DYKCGSPSDS STTEEMEVAV SKARAKVTMN DFDYLKLLGK GTFGKVILVR EKATGRYYAM
     KILRKEVIIA KDEVAHTVTE SRVLQNTRHP FLTALKYAFQ THDRLCFVME YANGGELFFH
     LSRERVFTEE RARFYGAEIV SALEYLHSRD VVYRDIKLEN LMLDKDGHIK ITDFGLCKEG
     ISDGATMKTF CGTPEYLAPE VLEDNDYGRA VDWWGLGVVM YEMMCGRLPF YNQDHERLFE
     LILMEEIRFP RTLSPEAKSL LAGLLKKDPK QRLGGGPSDA KEVMEHRFFL SINWQDVVQK
     KLLPPFKPQV TSEVDTRYFD DEFTAQSITI TPPDRYDSLG LLELDQRTHF PQFSYSASIR
     E
//
